Watch ORMP. Know when insiders buy.
One email the day a filing lands. Free.
ORMP
ORAMED PHARMACEUTICALS INC.
4.79
+0.07 +1.48%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
22
FLAG · shorts 22
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $199.3MP/E 1.2DIV YIELD —FCF YIELD -2.62%REV TTM —NET INCOME $174.9MNET DEBT $59.3M52W 2.19 – 5.34SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.8M | $78.2M | +488.2% | 1.84 | −$200K | $2K | −$202K | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$3.7M | $38.3M | — | 0.91 | −$2.9M | $5K | −$2.9M | May 19 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$5.7M | $10M | — | 0.24 | −$466K | $2K | −$468K | Mar 26 |
| Q3 2025 · Sep 30 | $0 | — | — | −$2.4M | $48.4M | — | 1.13 | −$1.6M | $0 | −$1.6M | Nov 13 |
| Q2 2025 · Jun 30 | $0 | — | — | −$2.5M | $13.3M | +44.2% | 0.31 | −$3.5M | $4K | −$3.5M | Aug 10 |
| Q1 2025 · Mar 31 | $2M | — | 0.7% | −$4.5M | −$7.6M | −597.5% | -0.19 | −$3.5M | $3K | −$3.5M | May 19 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.6M | −$10.2M | −179.0% | -0.26 | −$1.9M | $11K | −$1.9M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$3.1M | −$19.6M | — | -0.48 | −$7.1M | $5K | −$7.1M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$3.1M | $9.2M | — | 0.22 | $2.1M | $0 | $2.1M | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3M | $1.5M | — | 0.04 | −$1.5M | $2K | −$1.5M | May 15 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$3.9M | $12.9M | — | 0.33 | −$1.4M | $3K | −$1.4M | Mar 27 |
| Q3 2023 · Sep 30 | $0 | — | — | −$2.9M | −$3.2M | — | -0.08 | −$694K | $32K | −$726K | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2M | 0.7% | −$15.1M | $64M | 3202.5% | 1.50 | −$9.1M | $9K | −$9.2M | $4.7M | — |
| FY2024 · to Dec 31 | — | — | −$12.8M | −$19.1M | — | -0.48 | −$8.4M | $18K | −$8.4M | $2.5M | — |
| FY2023 · to Dec 31 | $1.3M | — | −$15.8M | $5.1M | 379.7% | 0.14 | −$10.3M | $254K | −$10.5M | — | — |
| FY2022 · to Dec 31 | $2.7M | — | −$40.6M | −$36.6M | -1352.6% | -0.94 | −$27.9M | $496K | −$28.4M | — | — |
| FY2021 · to Aug 31 | $2.7M | — | −$24.2M | −$23M | -850.5% | 0.78 | −$21.2M | $375K | −$21.6M | — | — |
| FY2020 · to Aug 31 | $2.7M | — | −$11.8M | −$11.5M | -424.8% | 0.56 | −$12.4M | $82K | −$12.5M | — | — |
Every number comes from ORAMED PHARMACEUTICALS INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.